Abstract: There is disclosed compositions and methods for treating or preventing cardiovascular conditions by intravascular administration of an omega fatty acid to a patient in need thereof. The omega fatty acid is intravascularly administered preferably in close proximity to the treatment site. Cardiovascular conditions which may be treated or prevented according to this invention include coronary artery disease, myocardial infarction, cerebrovascular disease, stroke, peripheral vascular disease, and atherosclerosis or thrombosis of arteries or veins supplying any organ system. Thrombosis or restenosis occurring in grafts, stents, and in areas of diagnostic or therapeutic intervention such as angioplasty or diagnostic radiology sites can also be treated or prevented.

Abstract: Methods are disclosed for treating neurotransmitter-mediated pain syndromes such as fibromyalgia. Such methods include topically administering an effective amount of a composition containing an omega fatty acid in combination with a carrier or diluent. The composition may also contain a cyclo-oxygenase inhibitor and other optional components, such as vitamins A, E and/or C.

Abstract: There is disclosed a composition and method for reducing or alleviating the discomforting symptoms associate with menstruation, particularly menstrual pain. The composition is administered by topical or local administration to the uterus or vaginal tissues of a women in need thereof, and contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include, ibuprophen, acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.

Abstract: There is disclosed compositions and methods for inhibiting inflammation and/or adhesion formation in a patient. The compositions comprise omega-3 and/or omega-6 fatty acids, a nonionic surfactant, and a pharmaceutically acceptable carriers or diluents. The omega fatty acid compositions may optionally contain cyclooxygenase inhibitors and other additives and preservatives such as dextrose and vitamin A. The methods of inhibiting inflammation and/or adhesion formation in a patient comprise administration of an effective quantity of a composition to a body cavity of the patient.

Abstract: There is disclosed a composition for inhibiting uterine contractility by topical or local administration. The composition contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.